$GLUE SEC Filings

Filed On	Filing
06 Oct 2026	Form 4: Bowen Matthew, Principal Accounting Officer Sold 13 shares ($137)
01 Oct 2026	8-K: Regulation FD Disclosure; Other Events Degrading Proteins, Making Medicines MRT-8102 GFORCE-1 Clinical Study Results October 1, 2026 Exhibit 99.2
08 Sep 2026	8-K: Regulation FD Disclosure; Other Events Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G
06 Aug 2026	10-Q
06 Aug 2026	8-K: Results of Operations and Financial Condition
17 Jul 2026	Form 4: Warmuth Markus, Director Sold 9,500 shares ($220K)
16 Jul 2026	Form 4: Champoux Jennifer, Chief Operating Officer Received 4,351 shares by exercise or conversion ($17.3K) · Sold 4,351 shares ($102K)
16 Jul 2026	144
15 Jul 2026	144
08 Jul 2026	SCHEDULE 13G/A
07 Jul 2026	Form 4: Townson Sharon, Chief Scientific Officer Received 6,000 shares by exercise or conversion ($36.8K) · Sold 6,000 shares ($140K)
06 Jul 2026	Form 4: Behbahani Ali, Director Disposed of 1,015,000 shares (Other Transaction) · Acquired 15,000 shares (Other Transaction)
06 Jul 2026	SCHEDULE 13D/A
01 Jul 2026	Form 4: Janku Filip, Chief Medical Officer Received 5,407 shares by exercise or conversion ($72.5K) · Sold 5,407 shares ($132K)
30 Jun 2026	144
30 Jun 2026	Form 4: Janku Filip, Chief Medical Officer Received 6,000 shares by exercise or conversion ($45.4K) · Sold 6,000 shares ($138K)
30 Jun 2026	Form 4: Manning Anthony M., Director Received 10,000 shares by exercise or conversion ($41.6K) · Sold 10,000 shares ($231K)
29 Jun 2026	144

Comments